Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer
- PMID: 16912162
- DOI: 10.1158/0008-5472.CAN-06-0486
Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer
Abstract
Pathways mediated by p53 and Rb are frequently altered in aggressive human cancers, including prostate carcinoma. To test directly the roles of p53 and Rb in prostate carcinogenesis, we have conditionally inactivated these genes in the prostate epithelium of the mouse. Inactivation of either p53 or Rb leads to prostatic intraepithelial neoplasia developing from the luminal epithelium by 600 days of age. In contrast, inactivation of both genes results in rapidly developing (median survival, 226 days) carcinomas showing both luminal epithelial and neuroendocrine differentiation. The resulting neoplasms are highly metastatic, resistant to androgen depletion from the early stage of development, and marked with multiple gene expression signatures commonly found in human prostate carcinomas. Interestingly, gains at 4qC3 and 4qD2.2 and loss at 14qA2-qD2 have been consistently found by comparative genomic hybridization. These loci contain such human cancer-related genes as Nfib, L-myc, and Nkx3.1, respectively. Our studies show a critical role for p53 and Rb deficiency in prostate carcinogenesis and identify likely secondary genetic alterations. The new genetically defined model should be particularly valuable for providing new molecular insights into the pathogenesis of human prostate cancer.
Similar articles
-
Prostate cancer associated with p53 and Rb deficiency arises from the stem/progenitor cell-enriched proximal region of prostatic ducts.Cancer Res. 2007 Jun 15;67(12):5683-90. doi: 10.1158/0008-5472.CAN-07-0768. Epub 2007 Jun 6. Cancer Res. 2007. PMID: 17553900
-
Conditional deletion of Rb causes early stage prostate cancer.Cancer Res. 2004 Sep 1;64(17):6018-25. doi: 10.1158/0008-5472.CAN-03-2509. Cancer Res. 2004. PMID: 15342382
-
Alterations of p53 are common in early stage prostate cancer.Can J Urol. 2003 Aug;10(4):1924-33. Can J Urol. 2003. PMID: 14503938 Review.
-
Sex hormone-induced carcinogenesis in Rb-deficient prostate tissue.Cancer Res. 2000 Nov 1;60(21):6008-17. Cancer Res. 2000. PMID: 11085521
-
Molecular biology of prostate cancer.Semin Oncol. 1994 Oct;21(5):514-21. Semin Oncol. 1994. PMID: 7939745 Review.
Cited by
-
Tissue-Based Diagnostic Biomarkers of Aggressive Variant Prostate Cancer: A Narrative Review.Cancers (Basel). 2024 Feb 16;16(4):805. doi: 10.3390/cancers16040805. Cancers (Basel). 2024. PMID: 38398199 Free PMC article. Review.
-
Molecular Mechanisms of Prostate Cancer Development in the Precision Medicine Era: A Comprehensive Review.Cancers (Basel). 2024 Jan 25;16(3):523. doi: 10.3390/cancers16030523. Cancers (Basel). 2024. PMID: 38339274 Free PMC article. Review.
-
Prostate Cancer Liver Metastasis: An Ominous Metastatic Site in Need of Distinct Management Strategies.J Clin Med. 2024 Jan 27;13(3):734. doi: 10.3390/jcm13030734. J Clin Med. 2024. PMID: 38337427 Free PMC article. Review.
-
ADORA2A-driven proline synthesis triggers epigenetic reprogramming in neuroendocrine prostate and lung cancers.J Clin Invest. 2023 Dec 15;133(24):e168670. doi: 10.1172/JCI168670. J Clin Invest. 2023. PMID: 38099497 Free PMC article.
-
Targeting Key Players of Neuroendocrine Differentiation in Prostate Cancer.Int J Mol Sci. 2023 Sep 5;24(18):13673. doi: 10.3390/ijms241813673. Int J Mol Sci. 2023. PMID: 37761978 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous